Nuaman Tyyeb is the Executive Chairman and Co-Founder of COPILOT Provider Support Services, and has been instrumental in leading the company to sustained double digit growth through the development of proprietary healthcare reimbursement technology. Nuaman became an entrepreneur in college when he started a telecommunications company called Digital Access Networks. Then, at age 26, Tyyeb transitioned into specialty pharmaceutical healthcare when he co-founded CareMed Specialty Pharmacy. Nuaman helped lead CareMed and grew it to over $250MM in revenue. It was sold in 2017 to PharMerica, a leading provider of pharmacy services.

Under Nuaman’s leadership, COPILOT maintained operations throughout the COVID-19 Pandemic by remoting staff and enhancing its technology platforms. During this challenging time, COPILOT actually onboarded two new clients, obtained a non-dispensing pharmacy license and expanded its corporate footprint to Orlando, FL. In 2021, Nuaman was recognized as one of Crain’s New York “40 Under 40” proven leaders in business.

Nuaman has a Bachelor of Science in Economics with a minor in Computer Science from SUNY Stony Brook and he is a member of the National Association of Specialty Pharmacy. He has received a number of recognitions from the New York State Senate, the New York State Assembly and the towns of North Hempstead and Oyster Bay.

Vern is responsible for transaction origination and execution, portfolio company value creation initiatives, and investment policy. Mr. Davenport is a member of the Private Equity investment committee.

Before joining QHP Capital, Mr. Davenport was CEO and Board Member at Medfusion. He was instrumental in the carve-out of the company from Intuit and returning its core portal solution to a market leadership position. Prior to Medfusion, Mr. Davenport was Chairman and CEO of Medquist, a leader in transcription services before and after the privatization of the company. Mr. Davenport facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take-private process.

Mr. Davenport’s previous experience also includes his time as President, Allscripts; CEO, Misys Healthcare; GM and EVP, Kodak Health Group (now Carestream Health), and executive leadership roles at Siemens and Shared Medical Systems. Mr. Davenport started his career at IBM where he spent 11 years in sales, sales leadership, and executive management positions.

Education

BSBA in Business from East Carolina University

MBA from East Carolina University

Dr. Moby Kazmi is the President and Co-Founder of COPILOT. In this role, he has led the development of some of the most innovative bio-pharma reimbursement HUB solutions which have been specifically designed to overcome access to treatment barriers and improve patient outcomes. Under Moby’s leadership, COPILOT has continued to provide clients with efficient and effective patient reimbursement and clinical support services, illustrated by COPILOT’s 95% same day completion rate of patient benefit verifications. Dr. Kazmi has played an integral role in helping to develop COPILOT’s digital platform and was instrumental in the development of a design that provides healthcare professionals and bio-pharma clients with instantaneous data regarding patient insurance approval. His work has led to COPILOT’s services becoming a cornerstone in the commercial success of many essential drug and device products.

As part of COPILOT, Moby established and drives COPILOT Cares, a charitable initiative that benefits underprivileged children and families around the world through a variety of philanthropic efforts. One of COPILOT Cares’ key investments is the installation of hand pumps for clean water where access is lacking. To date, COPILOT Cares has installed more than 400 hand pumps in India, Bangladesh, Pakistan, and Sri Lanka, providing clean water to families on a global scale.

Prior to this, Moby co-founded CareMed Specialty Pharmacy. It quickly gained recognition as one of the nation's fastest growing, privately held companies by Inc. Magazine. By December 2013, annual sales surpassed $250MM. PharMerica, a leading provider of pharmacy services, acquired CareMed in March 2017.

In 2023, Ernst and Young recognized Dr. Kazmi as a 2023 Entrepreneur of the Year (EY Award) Finalist. Dr. Kazmi was selected by an independent panel of judges. Entrepreneurs were evaluated based on their demonstration of building long-term value through entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes. In 2021, the Orlando Business Journal announced Dr. Kazmi as one of its "CEOs of the Year", an honor shared by top executives in the region who make both an economic and community-wide impact. Moby was also recently recognized as one of the National Minority Quality Forum’s top “Forty Under 40” Leaders in Minority Health, due to his achievements in eliminating health disparities. He serves on the Board of Directors for AdventHealth for Children (formerly Florida Hospital for Children), Bali Memorial Trust and Helping Hands Foundation. In addition, he has received several citations from the New York State Senate, the New York State Assembly, the Towns of North Hempstead and Oyster Bay, NY, MLB NY Mets’ Spirit Award, and Entrepreneur and Philanthropist of the Year Award from the Friends for Good Health Organization. He was recognized by the Nassau County Executive for his entrepreneurship, philanthropy, and service as a global goodwill ambassador as well. Moby earned his Medical Doctorate Degree from Avalon School of Medicine and his undergraduate degree in Psychology from Stony Brook University.

Education

Bachelor of Science in Psychology from SUNY Stony Brook

Medical Doctorate from Avalon School of Medicine

Michael is responsible for transaction origination and execution, portfolio company value creation initiatives, investment policy, and investor relations. Mr. Sorensen is a member of the Private Equity investment committee.

Prior to joining QHP Capital, Mr. Sorensen was a director in BlackRock’s private equity group. In that role he was responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology, and consumer/retail, among others.

Prior to BlackRock, Mr. Sorensen worked at Sorenson Capital (no familial relation), a mid-market private equity firm based in Salt Lake City. Similar to his current role, he analyzed private companies in a wide range of industry sub-sectors and geographies. Mr. Sorensen also worked as a consultant for L.E.K. Consulting in Los Angeles, where he worked closely with clients’ senior management on projects that included asset optimization, strategic planning, and customer segmentation, primarily in the healthcare and media industries.

Education

Bachelor of Science in Economics from Brigham Young University with Honors.

MPA from Harvard University.

MBA from the Wharton School at the University of Pennsylvania.

Faisal is a healthcare executive leader with proven results at some of the most successful healthcare technology companies; Change Healthcare (NASDAQ: CHNG), Allscripts Healthcare (NASDAQ: MDRX) and Neoforma (NASDAQ: NEOF).

Faisal has built new and has turned-around SaaS based businesses. He has led multiple P&Ls, simultaneously. He has launched healthcare data solutions, clinical interoperability solutions, Electronic Medical Record (EMR) solutions, Revenue Cycle Management (RCM) solutions, Patient Access solutions and clinical trials recruitment solutions. Faisal has built and scaled global organizations of 2200+ team members.

Most recently, Faisal founded a division at Change Healthcare and grew it to $45M+ rev, 50+% margin. The Clinical Networks Division operated the largest national clinical interoperability network, enabling clinical data exchange among providers, and with health plans. The network is in use by health plans and Change Healthcare’s Payer Analytics business units. Faisal led strategic venture investment in BEK Health, a provider of AI based clinical trials recruitment.

Faisal also founded Veradigm, the fastest growing business at Allscripts Healthcare Solutions with revenue exceeding $160M+ and 60+% margin. He was one of the executive leaders responsible for growing Allscripts from 600 employees to over 7,000 employees and from $350 million in revenue to over $1.6 billion in annual revenue. He led the majority acquisition of Pulse8, a provider of Payer Analytics for ACA plans.

Faisal led product/r&d integration for Misys/Allscripts’s $800M merger and Allscripts/Eclipsys’s $1.5B merger. He rationalized complex portfolios and achieved M&A synergy goals.

As the CEO of Truveris, a cloud-based solution for drug price transparency, Faisal led growth in revenue from $9.4M to $34.2M over a two-year period. He achieved positive cash flow and raised $25M in growth funding led by McKesson Ventures after a highly competitive process.

Faisal has been a frequent speaker at industry conferences such as CNBC Healthy Returns summit. He has co-authored four patents in sentiment analysis (Natural Language Processing) and Machine Learning (ML) techniques for processing large data sets.

Education

Advanced Management Program at the Harvard Business School

BS in Computer Science and a BS in Electrical Engineering from University of Wisconsin, Madison

Chuck Stevens is the chief executive officer of COPILOT. He leverages almost three decades of bio-pharmaceutical industry experience to lead the executive team and drive the company’s transformational HUB strategies. Before being named CEO in 2023, he served as COPILOT’s chief operating officer, where he developed strategic operations plans to support revenue and market share and was responsible for strategic reimbursement, pricing, payer strategy, product distribution, medical communications, payer marketing, and HEOR modeling.

Chuck specializes in hematology, oncology, infectious diseases, addiction medicine, CNS, OA, and rare disorder products. Before joining COPILOT, Chuck served as the president of MediMedia/CHC and head of global access and commercialization at ICON and led a team of over 400 life science consultants. Prior to this, he was the vice president and general manager of PAREXEL’s reimbursement HUB, health policy, and market access consulting practice. In the past, Chuck also held commercial positions at Cephalon Oncology, Cell Therapeutics, Genetics Institute (Wyeth Oncology), and Abbott Laboratories.

Chuck is a former Captain in the United States Army and a veteran of Operation Desert Storm. He graduated from Northeastern University with a Bachelor of Science degree in Business Administration. He has an MBA from Clark University, a Juris Doctor Degree from Suffolk University Law School, and attended the Massachusetts Senior Executive Program at Harvard University’s John F. Kennedy School of Government. Chuck is a member of the Bar of the Supreme Court of the United States and of the Commonwealth of Massachusetts.

Education

BS in Business Administration from Northeastern University

MBA from Clark University

Juris Doctor from Suffolk University Law School